Department of Health [47] | 2009 | UK | Pooled routine data | Governmental assessment | Total treatment costs | 2009 | “Normal” and drug-resistant TB | NA | No distinction between inpatients and outpatients |
White et al. [35] | 2000 | UK | Retrospective analysis | Hospital data from St Bartholomew’s Hospital, London | Total treatment costs of adult HIV-negative patients | 2000 | Drug-susceptible and MDR-TB | 9 MDR-TB and 18 drug-susceptible TB patients matched by age group and ethnicity 1996–1999 | Local data, not representative of UK |
Deuffic-Burban et al. [36] | 2010 | France | Modelling per patient | Unit costs were obtained from the French registers and drug costs from the pharmacy records of Tourcoing Hospital, Tourcoing | Total treatment costs | 2007 | Drug-susceptible TB only | NA | Figures embedded in cost-effectiveness analysis of latent TB infection diagnostics |
French National Assembly# [37] | 2011 | France | Pooled routine data | Governmental assessment | Medication costs only | 2009 | Drug-susceptible TB, MDR-TB and XDR-TB | NA | |
Bocchino et al. [38] | 2006 | Italy | Retrospective analysis | Division of Respiratory Medicine,University of Tor Vergata, “L Spallanzani”, Rome | Total treatment costs of adult HIV-negative patients | 2002 | Drug-susceptible TB and MDR-TB | Review of the medical records of 92 TB cases 2000–2003 | Local data, not representative of Italy |
Montes-Santiago et al. [39] | 2004 | Spain | Retrospective analysis | Recalculation of governmental data (weighted averaging) | Total treatment costs | 2006 | Drug-susceptible TB only | Evaluation of routine data | TB patients assigned to the respective diagnosis-related groups |
Rajalahti et al. [40] | 2004 | Finland | Retrospective analysis | Combined annual data of two University Hospital Districts (Pirkanmaa and Varsinais-Suomi) | Total treatment costs | 2000 | Susceptible TB only | 27 culture-proven pulmonary TB patients | Local data, not representative of Finland |
Diel et al. [41] | 2012 | Germany | Modelling per patient | Weighted averaging of cost data, provided separately for children and adults | All types of costs calculated | 2010 | Drug-susceptible and MDR-TB | All TB cases reported in 2010 included | Epidemiological data and unit costs assessed according to the German public health insurance system |
Blaas et al. [42] | 2008 | Germany | Retrospective analysis | Averaging of individual cost occurring in the University Hospital Regensburg, Regensburg | Total treatment costs | 1998–2003 | XDR-TB only | 4 XDR-TB patients 1998–2003 | |
Eker et al. [43] | 2008 | Germany | Retrospective analysis | 27 participating hospitals | Duration of hospitalisation | NA | MDR-/XDR-TB patients only | 177 MDR-TB and 7 XDR-TB cases 2004–2006 | 37% of all culture-confirmed TB cases in Germany included |
de Vries et al. [44] | 2013 | The Netherlands | Retrospective analysis | Costs derived from the official National Institute for Public Health and the Environment (RIVM) and Royal Netherlands Tuberculosis Association (KNCV) Tuberculosis Foundation data | Total treatment costs | 2009 | Drug-susceptible, MDR- and XDR-TB | 1138 patients with non-MDR-TB and 20 with MDR-/XDR-TB | Complete countrywide review |
Belgian Lung and Tuberculosis Association [48] | 2012 | Belgium | Pooled routine data | Governmental assessment | Medication costs only | 2012 | Drug-susceptible TB, MDR-TB and XDR-TB | NA | |
Rumetshofer [45] | 2008 | Austria | Retrospective analysis | Pharmacy records of the Otto Wagner Hospital, Vienna | Medication costs only | 2008 | Drug-susceptible TB, MDR-TB and XDR-TB | NA | |
Floyd et al. [46] | 2012 | Estonia | Retrospective cohort analysis | Average cost per patient treated according to World Health Organization guidelines | Total treatment costs | 2003 | MDR-TB only | Cohort of 149 TB cases (enrolled 2001–2002) followed | |